Previous 10 | Next 10 |
RTX-240 Investigational New Drug Application for Cancer on File with U.S. Food and Drug Administration Rubius Manufacturing Facility Operational Nine Months Ahead of Schedule and Ready to Supply Future Clinical Trials Focus on Clinical Development to Advance Three Distinct Therapeutic...
CAMBRIDGE, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced the appointment of Laurence Turka, M...
CAMBRIDGE, Mass., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, announced today that Pablo J. Cagnoni, M.D., ch...
Rubius Therapeutics (NASDAQ: RUBY ) appoints Christina Coughlin, M.D., Ph.D., as the Company’s Chief Medical Officer (CMO), effective January 6, 2020. More news on: Rubius Therapeutics, Inc., Healthcare stocks news, Read more ...
CAMBRIDGE, Mass., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced the appointment of Christina Coughli...
CAMBRIDGE, Mass. , Dec. 19, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today announced the launch of Ring Therapeutics, an early-stage biotechnology company developing first-in-class gene therapies using a new viral vector platform based...
CAMBRIDGE, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced the appointment of Anne Prener, M.D....
Preliminary data from a Phase 1/2 clinical trial, pheNIX , evaluating Homology Medicines' (NASDAQ: FIXX ) gene therapy HMI-102 in patients with phenylketonuria (PKU) showed encouraging action. More news on: Homology Medicines, Inc., Synlogic, Inc., BioMarin Pharmaceutical Inc., Healthc...
The following slide deck was published by Rubius Therapeutics, Inc. in conjunction with this Read more ...
Aravive's Reverse Merger Path to Public Company Creates Potentially Compelling Overlooked and Underfollowed Investment Opportunity If a company chooses to go public through a reverse merger instead of the more conventional IPO path, it has a higher chance to become an Overlooked and Underf...
News, Short Squeeze, Breakout and More Instantly...
Rubius Therapeutics Inc. Company Name:
RUBY Stock Symbol:
OTCMKTS Market:
Rubius Therapeutics Inc. Website:
iClick Interactive Asia Group Limited (ICLK) is expected to report for quarter end 2023-09-30 Applied Minerals Inc (AMNL) is expected to report for quarter end 2023-09-30 Banco Do Brasil S.A. ADR (BDORY) is expected to report for Q3 2023 Rubius Therapeutics Inc. (RUBY) is expected to ...
American Bio Medica Corp. (ABMC) is expected to report for quarter end 2023-09-30 Surgalign Holdings Inc. (SRGAQ) is expected to report for quarter end 2023-09-30 MillerKnoll Inc. (MLKN) is expected to report $0.52 for Q2 2024 Ping AN Insurance (Group) Co. of China, Ltd. ADR - Level I...
Epiroc AB ADR (EPOKY) is expected to report for Q3 2023 Sysmex Corporation ADR (SSMXY) is expected to report for Q2 2024 Streamline Health Solutions Inc. (STRM) is expected to report for Q1 2024 Helix Biopharma Corp. (HBPCF) is expected to report for Q2 2024 Standard Chartered plc...